文献速递精神分裂症与精神病性障碍

大麻二酚(CBD)作为精神分裂症辅助治疗:多中心随机对照试验

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
PubMed 文献 · Am J Psychiatry · 2017-12-15

这项探索性双盲平行组试验将精神分裂症患者按1:1随机分配至CBD(1000 mg/天;N=43)或安慰剂(N=45)组,并维持原有抗精神病药物治疗。治疗6周后,CBD组阳性精神病性症状水平低于安慰剂组(PANSS治疗差异=-1.4,95% CI=-2.5,-0.2),临床医生评定为改善(CGI-I治疗差异=-0.5,95% CI=-0.8,-0.1)及非严重病态(CGI-S治疗差异=-0.3,95% CI=-0.5,0.0)的可能性更高;认知表现和整体功能改善未达统计学显著性。CBD耐受良好,不良事件率与安慰剂组相似。

要点

  • CBD 1000 mg/天辅助治疗6周可减轻精神分裂症阳性症状,效应量较小。
  • CBD组临床总体改善和非严重病态评定优于安慰剂组。
  • 认知和整体功能改善未达统计学显著性,CBD耐受良好。

核心结论

  • CBD对精神分裂症患者具有有益效应,可能代表不依赖多巴胺受体拮抗的新型治疗类别。

研究设计与样本

  • 探索性双盲平行组试验,精神分裂症患者按1:1随机分配至CBD(1000 mg/天;N=43)或安慰剂(N=45),联合原有抗精神病药物治疗。
  • 治疗前后采用PANSS、BACS、GAF、CGI-I和CGI-S进行评估。

主要发现

  • 治疗6周后,CBD组阳性精神病性症状水平低于安慰剂组(PANSS治疗差异=-1.4,95% CI=-2.5,-0.2)。
  • CBD组被临床医生评定为改善的可能性更高(CGI-I治疗差异=-0.5,95% CI=-0.8,-0.1),被评定为非严重病态的可能性更高(CGI-S治疗差异=-0.3,95% CI=-0.5,0.0)。
  • CBD组认知表现(BACS治疗差异=1.31,95% CI=-0.10,2.72)和整体功能(GAF治疗差异=3.0,95% CI=-0.4,6.4)改善未达统计学显著性。
  • CBD耐受良好,不良事件率与安慰剂组相似。

关键数值与推荐

  • CBD剂量为1000 mg/天,治疗持续时间6周,联合原有抗精神病药物。
  • 主要疗效指标包括PANSS、CGI-I、CGI-S、BACS和GAF。

临床怎么用

  • 对于精神分裂症患者,可在原有抗精神病药物基础上考虑辅助使用CBD 1000 mg/天,可能改善阳性症状和临床总体印象。
  • 需注意认知和功能改善证据尚不显著,应个体化评估获益与风险。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. METHOD: In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using the Positive and Negative Syndrome Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S). RESULTS: After 6 weeks of treatment, compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms (PANSS: treatment difference=-1.4, 95% CI=-2.5, -0.2) and were more likely to have been rated as improved (CGI-I: treatment difference=-0.5, 95% CI=-0.8, -0.1) and as not severely unwell (CGI-S: treatment difference=-0.3, 95% CI=-0.5, 0.0) by the treating clinician. Patients who received CBD also showed greater improvements that fell short of statistical significance in cognitive performance (BACS: treatment difference=1.31, 95% CI=-0.10, 2.72) and in overall functioning (GAF: treatment difference=3.0, 95% CI=-0.4, 6.4). CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups. CONCLUSIONS: These findings suggest that CBD has beneficial effects in patients with schizophrenia. As CBD's effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. Am J Psychiatry. 2017. PMID: 29241357. doi:10.1176/appi.ajp.2017.17030325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。